In evaluable patients with low-grade glioma, this inhibitor reduced plasma 2-HG levels (a direct marker of IDH inhibition) by more than 90%, achieved a disease control rate of 100%, had a median PFS of approximately 20.5 months, and no dose-limiting toxicity was observed. This evidence concerns the gene IDH2 and glioma.